Are you 18 or older? Have you recently received a diagnosis of acute myeloid leukemia (AML) with certain gene changes? If you answered yes to both, you may be able to participate in an AML treatment study. We want to understand the effectiveness of the combination of a new anti-cancer drug called SNDX-5613 and the standard chemotherapy treatment.

You are being asked to participate in this research study because you have been diagnosed with breast cancer and considered for immunotherapy. This study will investigate your response to immunotherapy.

Do you have triple-negative breast cancer that either came back or did not improve after initial cancer treatment? If so, you may be able to take part in this gene therapy research study to learn more about using your own modified immune cells as a possible treatment.

Are you interested in improving your physical health and wellbeing during or after cancer treatment? If so, our free 12- week exercise program might be a good fit for you! We are creating a registry of adults with a cancer diagnosis who have gone through our program.

Do you have Stage II or III Breast cancer? If you have enough tissue from your breast cancer diagnosis to send for Mammaprint genomic testing, you may be able to take part in this research study. In this study, we want to learn more about adding an immunotherapy drug, durvalumab, to your chemotherapy treatment. The Mammaprint testing is conducted at no cost to you and the cost of durvalumab is covered.

Can we extend your life after the diagnosis of your cancer in the stomach, esophagus, or gastroesophageal junction by adding a third chemotherapy drug to the usual combination of two chemotherapy drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for treatment of your cancer in the stomach, esophagus, or gastroesophageal junction. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction.

To find out if the study drug AZD9829 is safe and tolerable and effective in treating blood cancer.

Is your child between the ages of 8-21, newly diagnosed with Leukemia or Lymphoma, and plans to receive chemotherapy treatment? If so, you may be able to participate in a research study investigating the feasiblity of a dietary intervention during treatment.

In this study, we want to find out if a combination of 3 different study drugs (Cabozantinib, Ipilimumab, and Nivolumab) will affect the progression of Soft Tissue Sarcoma.

You are asked to participate in this research study of a new immunotherapy combination with chemotherapy in metastatic triple negative breast cancer. Immunotherapy is a form of cancer therapy that activates a patient's immune system to fight the cancer in a patient's body. Unfortunately, only a limited number of patients with metastatic triple negative breast cancer currently respond to FDA approved forms of immunotherapy. CDX-301 and CDX-1140 are two new immunotherapy drugs that are thought to kickstart the immune response against cancers even in patients who do not have an adequate immune response against their cancer to start with. Some studies suggest that combining these drugs with chemotherapy can most effectively kickstart this immune response and lead to improved clinical outcomes.